Ocuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings

Ocuphire Pharma announced two presentations featuring efficacy and safety results from the Company’s recently completed ZETA-1 Phase 2 trial of oral APX3330 in diabetic retinopathy, DR, at two medical meetings in February. Peter Kaiser, M.D. presented the results at the Angiogenesis, Exudation, and Degeneration 2023 Meeting held virtually on February 10-11, 2023. Rishi P. Singh, M.D. will present at the upcoming Macula Society 46th Annual Meeting, to be held in-person February 15-18, 2023 in Miami, FL. Dr. Kaiser’s presentation, titled "Efficacy and Safety Data for APX3330, a Novel Oral Drug Candidate for DR/DME, from the ZETA-1 Phase 2 Trial," discussed results from the trial during the Diabetic Retinopathy Imaging and Treatment session at the 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting on Saturday, February 11th organized by the Bascom Palmer Eye Institute. Oral APX3330 achieved statistical significance on a key pre-specified secondary DRSS endpoint of preventing clinically meaningful progression of DR after 24 weeks of treatment. In addition, APX3330 demonstrated a favorable systemic and ocular safety and tolerability profile.